

Part 2

Aggregation Analysis and Oligo Size Exclusion (SEC) looking at both Aggregation analysis of mABs and Oligo therapeutics purification and identification

3-Part Series

LIVE WEBCAST

Wednesday, March 30, 2022

11am SST | 12pm JST | 3am GMT | 4am CET

Presenters



Anne Blackwell, PhD

Biocolumns Product Manager
Agilent Technologies, Inc.



Matthew L. Turner, PhD

Biocolumns Product Manager
Agilent Technologies, Inc.

Moderator



Chris Spivey

Editorial Director
BioPharm International

For questions email
jramesh@mjhlifesciences.com



Register for this free webcast at:

www.biopharminternational.com/bp_p/glycomics

Event Overview

With the enormous potential of oligonucleotide therapeutics, there is more interest than ever in choosing the best tools for oligonucleotide synthesis, analysis, and purification.

Given the complex impurity profiles, varying sequence modifications, and lengths, thoughtful optimization of HPLC methodologies for characterization and purification is essential to obtain pure oligonucleotides for research, diagnostics, and therapeutics.

This webinar will discuss the common challenges associated with oligonucleotide analysis and purification, focusing on Agilent's suite of Bio LC column solutions designed to address the complex needs of the market.

Key Learning Objectives

The following will be covered:

- Technical challenges and impurities associated with oligonucleotide synthesis
- Oligonucleotide analysis with varying oligonucleotide structures (size, modifications)
- AEX vs IP-RP and the best choice based on purity, scale, temperature, and instrumentation
- Method optimization considerations
- Scaling up your purification

Who Should Attend

- QA/QC laboratories
- Biopharma analytical development scientists
- Biopharma process development scientists
- CDMO labs
- Diagnostic development labs

Sponsored by



Presented by

